The content on this site is intended for healthcare professionals only
Prof Mohamad Mohty speaks to ecancer about how the COVID-19 pandemic has affected the treatment of ALL.
He says that patients inflicted by haematological malignancies are in an immuno-suppresive state and are highly susceptible to COVID.
Their age can often make them more vulnerable too.
He says treatment of these patients should hence be done keeping all these factors in mind and should not be delayed.
He further highlights a few treatment modalities for different types of ALL and the risks attached to it.
In the end, he talks about how the problems arising by COVID-19 can be managed safely and promptly through appropriate management.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
ELCC 2025: Latest in EGFR positive NSCLC
SIOG 2024: Updates in medical oncology
Understanding cognitive impairment for elderly patients undergoing CAR T therapy
SIOG 2024: Updates in haematology
CDK4/6 inhibitors and endocrine therapy in elderly female patients with advanced hormone receptor positive HER-2 negative BC
Fracture risk increases following cancer therapies for advanced prostate cancer
Geriatric interventions are beneficial in reducing treatment-related toxicity in older adults with cancer
Cancer in emergencies: What can we do better to protect the most vulnerable?
Multiple Myeloma: evolving paradigm - Panel Discussion
